May 26, 2022

Mawazo Writing Africa

Writing about the main

Why that common cold may help you fight Covid-19

The study published by researchers at Imperial College London in the journal Nature Communications found that people with higher T cells (immune fighters) could get better from colds Have a chance if they come into contact with the coronavirus.

Dr. Ahmed Kalebi, a consulting pathologist who was not involved in the study, told Nation Tuesday that T cells are known to directly attack and destroy infectious microorganisms such as viruses and bacteria by destroying them Get in direct contact with the infectious microorganism and use chemical compounds to destroy them.

The researchers tried to find out why some people who have been exposed to the coronavirus fail to do so infect, although all odds show that they put themselves at risk of contracting the virus.

Study participants were divided into two groups; those who had a positive test and those who had a negative test.

T cells

Bei In the participants who had a negative Covid-19 test, the researchers found that they had high numbers of “memory” T cells from a cold, which they linked to the negative test result.

< p class = "align- -justify"> Dr. Kalebi explained that a cold is caused by different viruses and the coronavirus family is one of them.

“The most common viruses that cause a cold are rhinovirus, coronavirus, Respiratory Syncytial Virus (RSV) and Parainfluenza Viruses, in that order, “he explained.

The researchers rated people who were found positive for Covid-19 and traced theirs earliest contact with the coronavirus.


Dr Kalebi said that memory T cells that have previously attacked other viruses that the colds can cross-react with SARS-COV-2.

“Cross-reacting means that any chemical such as cytokines produced by the immune cells targeting a type of virus that will react with that targeted virus and whatever T cells they produce that target that V irus work, they end up reacting against other viruses that the immune cells are not targeting, so they react cross-reacting, like crossfire means targeting a certain enemy, but its firepower ends up hitting others who are not being targeted, “he explained.

“The study has now identified epitopes (viral components) between SARS-COV-2 and other viruses that cause colds, which are the targets for T-cell attachment are, “said Dr. Kalebi.

Covid-19 variants

Research has shown that the study with the advent of new Covid -19 variants in the development of new vaccines may help the future vari ants.

“Our study complements the small but growing amount of evidence that T cells protect against SARS-CoV-2 infection and supports the potential benefits of second generation vaccines that target core proteins, ”the study says.

Dr. Kalebi told the nation that T cells are like master keys that can open multiple locks, making them a great strategy for scientists in developing vaccines in the future.

” Developing vaccines that are designed to promote T-cell immunity and are able to cross-react between viruses could be a better strategy than vaccines that act via antibodies, as antibodies are highly specific and thus are limited to the target virus, “he explained.

However, the researchers insist that the current vaccines offer protection and that people who previously had a cold can still get away shouldn’t feel safe.

“While this is an important discovery, it is only a form of protection, and I want to emphasize that it should not be relied on by itself. Instead, the best way to protect yourself against Covid-19 is to be fully vaccinated, including a booster dose, “said Dr. Rhia Kundu, lead researcher on the study, in an article published by Imperial College London.

Another study published last year by researchers at Yale University in the Journal of Experimental Medicine also showed that people who catch a cold in the early days of a Covid-19 cold have their antiviral defenses quite high.

” Triggering these defense mechanisms early in the course of Covid-19 infection promises to prevent or treat the infection, “said Ellen Foxman, lead researcher on the study and assistant professor of laboratory medicine and immunobiology at the Yale School of Medicine Article published on the Yale University website.

[emailprotected] < / em>